Based on this finding, enrollment of Japanese patients is currently ongoing in two global, randomized phase 3 studies of vepdegestrant in patients with ER+/HER2- advanced breast cancer, with sites in the Asia–Pacific region. Here, ESR1 is linked to breast cancer.